Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. (NASDAQ: XGN) is a leading provider of advanced diagnostic solutions focused on autoimmune rheumatic diseases. With its headquarters in Carlsbad, California, Exagen operates a CLIA-certified and CAP-accredited laboratory dedicated to improving patient outcomes through innovative testing solutions.
Exagen's core business revolves around its Avise® brand, which encompasses a suite of ten proprietary diagnostic tests designed to provide accurate, timely, and differential diagnoses for autoimmune conditions like systemic lupus erythematosus (SLE) and rheumatoid arthritis. These tests empower physicians and patients with objective data to better manage and treat these complex diseases.
In recent developments, Exagen has entered an exclusive license agreement with Johns Hopkins University to develop novel lupus nephritis biomarkers. This collaboration aims to create non-invasive assays that offer unique clinical insights into lupus nephritis, enhancing diagnostic and treatment options.
Financially, Exagen reported revenue of $13.4 million for Q3 2023. Despite a net loss of $5.4 million for the same period, the company has shown improvements in key performance metrics such as adjusted EBITDA, which stood at $(3.6) million compared to $(6.1) million in Q3 2022. With cash and cash equivalents of $28.4 million as of September 30, 2023, Exagen is well-positioned to continue its growth and innovation.
Committed to personalized medicine, Exagen collaborates closely with community rheumatologists to ensure their diagnostic solutions meet the evolving needs of the medical community. Their focus on patient-centric care and continuous product enhancement underscores their mission to provide clarity in autoimmune disease decision-making.
For more detailed information, please visit the company's websites at exagen.com and avisetest.com.
Exagen Inc. (Nasdaq: XGN) announced that stockholders have elected Mr. Frank Stokes as an independent member of its Board of Directors during the Annual Meeting on June 17, 2021. Mr. Stokes will also chair the Audit Committee. His experience as a CFO and investment banker, particularly in the life sciences sector, is expected to contribute significantly to Exagen's growth strategy. He aims to enhance Exagen's commitment to improving patient care through innovative autoimmune testing solutions.
Exagen Inc. (Nasdaq: XGN) announced its participation in the William Blair 41st Annual Growth Stock Conference from June 1-3, 2021. The company will host a virtual fireside chat on June 2 at 11:20 AM EDT, featuring President and CEO Ron Rocca and CFO Kamal Adawi. Interested individuals can access the live webcast through Exagen’s website. Exagen focuses on autoimmune testing solutions, aiming to improve care for chronic autoimmune disease patients with innovative AVISE® testing products.
Exagen Inc. (XGN) reported a record revenue of $10.6 million for Q1 2021, up from $9.6 million in Q1 2020, driven by a significant increase in testing volumes. The company delivered 29,029 AVISE® CTD tests and achieved a record of 1,763 ordering healthcare providers. Operating expenses rose to $16.2 million, resulting in a net loss of $6.2 million, compared to a net loss of $5.6 million in the prior year. Exagen maintains its 2021 revenue guidance of $47 million to $49 million.
Exagen Inc. (Nasdaq: XGN) has entered a research collaboration and exclusive license agreement with Allegheny Health Network (AHN) to develop novel patented biomarkers for autoimmune diseases such as systemic lupus erythematosus (SLE). Exagen will gain exclusive rights to four distinct families of inventions and access to AHN's clinical biobank. The collaboration aims to enhance the existing AVISE® testing portfolio using advanced technology known as Cell-Bound Complement Activation Products (CB-CAPs), which were previously developed in conjunction with AHN researchers.
Exagen Inc. (Nasdaq: XGN) has announced its new campaign, 'Know With AVISE,' coinciding with Lupus Awareness Month. This initiative aims to educate the public on the importance of timely diagnosis and monitoring for Systemic Lupus Erythematosus (SLE). In collaboration with the Lupus Foundation of America and LupusChick, Exagen will focus on various stages of the lupus patient journey throughout May. The campaign highlights diagnostic challenges and health disparities while encouraging disease management. Exagen is committed to enhancing care for autoimmune disease patients through innovative testing solutions.
Exagen Inc. (Nasdaq: XGN) will release its financial results for Q1 2021 on May 11, 2021, after market close. A conference call hosted by executives including CEO Ron Rocca and CFO Kamal Adawi will take place at 4:30 PM ET to discuss the results. Interested parties can access the call through dial-in numbers or via the company's investor relations website. A replay will be available through May 18, 2021. Exagen focuses on autoimmune testing solutions and aims to enhance diagnosis and treatment for diseases like rheumatoid arthritis and lupus.
Exagen Inc. (Nasdaq: XGN) has announced a collaboration with Emory University to study the long-term effects of COVID-19 on autoimmune diseases. The longitudinal study will focus on biomarkers related to lupus and rheumatoid arthritis in mild/moderate COVID-19 patients, particularly those treated with dexamethasone. Dr. Ignacio Sanz from Emory emphasized the need for insights into the autoimmune response post-infection. Exagen's President and CEO, Ron Rocca, expressed excitement about leveraging their AVISE® testing portfolio to enhance patient care in this area.
Exagen Inc. (Nasdaq: XGN) has completed its public offering of 4,255,000 shares at $16.25 per share, generating approximately $69.1 million in gross proceeds. The funds will be allocated for developing Multi-omics capabilities, enhancing its clinical lab, and advancing its product pipeline, including tests for fibromyalgia, RA, and lupus nephritis. Exagen may also pursue strategic acquisitions but holds no current commitments. The offering was managed by Cowen, William Blair, and Cantor, among others.
Exagen Inc. (Nasdaq: XGN) announced a public offering of 3,700,000 shares at $16.25 each, aiming for gross proceeds of $60.1 million. The offering is expected to close around March 25, 2021. Exagen plans to use the proceeds for developing Multi-omics capabilities, advancing its product pipeline for tests related to fibromyalgia, RA, and lupus nephritis, enhancing intellectual property, and general corporate purposes. Underwriters have a 30-day option for an additional 555,000 shares.
Exagen Inc. (NASDAQ: XGN) announced plans for an underwritten public offering of its common stock, including a potential 15% over-allotment option for underwriters. The company intends to use the proceeds for enhancing its Multi-omics capabilities, advancing its product pipeline for disorders like fibromyalgia and lupus nephritis, and general corporate purposes. Exagen has no current commitments for acquisitions or investments. The offering is subject to market conditions, with no assurance of completion or terms.
FAQ
What is the current stock price of Exagen (XGN)?
What is the market cap of Exagen (XGN)?
What is Exagen Inc. known for?
Where is Exagen Inc. located?
What recent partnerships has Exagen Inc. entered into?
How did Exagen Inc. perform financially in Q3 2023?
What is the Avise® brand?
How does Exagen Inc. contribute to personalized medicine?
What is Exagen's mission?
What was Exagen's adjusted EBITDA for Q3 2023?
What resources does Exagen offer for lupus awareness?
How can I contact Exagen Inc. for investor relations?
